Harrow (NASDAQ:HROW) Price Target Raised to $60.00

Harrow (NASDAQ:HROW) had its price objective upped by stock analysts at HC Wainwright from $57.00 to $60.00 in a report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 145.90% from the stock’s previous close.

Separately, B. Riley cut their price objective on Harrow from $69.00 to $65.00 and set a “buy” rating on the stock in a report on Tuesday, April 1st.

Harrow Stock Up 3.4%

Shares of NASDAQ:HROW opened at $24.40 on Monday. The stock’s 50-day moving average price is $24.79 and its two-hundred day moving average price is $32.53. The firm has a market cap of $895.11 million, a price-to-earnings ratio of -25.96 and a beta of 0.41. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. Harrow has a 12-month low of $11.39 and a 12-month high of $59.23.

Harrow (NASDAQ:HROW) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.40). The firm had revenue of $47.83 million during the quarter, compared to analysts’ expectations of $57.00 million. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. On average, research analysts forecast that Harrow will post -0.53 EPS for the current year.

Institutional Investors Weigh In On Harrow

Several hedge funds have recently modified their holdings of HROW. Braidwell LP raised its holdings in shares of Harrow by 106.3% during the 4th quarter. Braidwell LP now owns 907,039 shares of the company’s stock valued at $30,431,000 after buying an additional 467,401 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Harrow by 443.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company’s stock valued at $10,717,000 after buying an additional 194,480 shares during the period. Two Sigma Investments LP raised its holdings in shares of Harrow by 483.2% during the 4th quarter. Two Sigma Investments LP now owns 150,355 shares of the company’s stock valued at $5,044,000 after buying an additional 124,574 shares during the period. Neuberger Berman Group LLC raised its holdings in shares of Harrow by 128.0% during the 4th quarter. Neuberger Berman Group LLC now owns 200,529 shares of the company’s stock valued at $6,728,000 after buying an additional 112,588 shares during the period. Finally, Trexquant Investment LP raised its holdings in shares of Harrow by 1,806.8% during the 4th quarter. Trexquant Investment LP now owns 94,500 shares of the company’s stock valued at $3,170,000 after buying an additional 89,544 shares during the period. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.